Results 21 to 30 of about 21,395 (260)

Hyperphosphatemia and Cardiovascular Disease [PDF]

Frontiers in Cell and Developmental Biology, 2021
Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of ...
Chao Zhou, Zhengyu Shi, Nan Ouyang, Xiongzhong Ruan, Xiongzhong Ruan   +4 more
openaire   +3 more sources

Research Models for Studying Vascular Calcification [PDF]

, 2020
Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen, Giet, Markus van der, Herrmann, Jaqueline, Schuchardt, Mirjam, Tölle, Markus   +4 more
core   +1 more source

Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: A cross-sectional study

Frontiers in Medicine, 2023
BackgroundHyperphosphatemia remains a major complication in patients with Continuous ambulatory peritoneal dialysis (CAPD) leading to increased morbidity and mortality. However, phosphorus management still has many challenges.ObjectiveThis study aimed to
Xiaojing Yin, Xiaojing Yin, Fan Zhang, Yan Shi   +3 more
doaj   +1 more source

EOS789, pan‐phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti‐GBM‐induced glomerulonephritis rats

Pharmacology Research & Perspectives, 2022
Hyperphosphatemia associated with chronic kidney disease (CKD) not only dysregulates mineral metabolism and bone diseases, but also strongly contributes to the progression of kidney disease itself.
Yoshinori Tsuboi, Yasuhiro Ichida, Atsuko Murai, Akira Maeda, Manami Iida, Atsuhiko Kato, Shuichi Ohtomo, Naoshi Horiba   +7 more
doaj   +1 more source

Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease

Journal of Veterinary Internal Medicine, 2021
Background Fibroblast growth factor (FGF)‐23 is increased first in the sequence of changes associated with chronic kidney disease (CKD)‐mineral and bone disorder.
Hirosumi Miyakawa, Huai‐Hsun Hsu, Mizuki Ogawa, Ryota Akabane, Yuichi Miyagawa, Naoyuki Takemura   +5 more
doaj   +1 more source

Psödohipoparatiroidi Tip 2: Olgu Sunumu

Genel Tıp Dergisi, 2021
Psödohipoparatiroidi, parathormona karşı hedef organ düzeyinde cevapsızlık nedeniyle hipokalsemi ve hiperfosfatemi gelişmesiyle karakterize bir bozukluktur.
Özlem Güleç Şen, Emre Kaçar, Tolga Altuğ Şen   +2 more
doaj   +1 more source

Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management. [PDF]

Nutrients
Raju S, Saxena R.
europepmc   +3 more sources

Vitamin D-Mediated Hypercalcemia in a Dog With Putative Cutaneous Pythiosis. [PDF]

Clin Case Rep
ABSTRACT A 12‐month‐old dog was diagnosed with cutaneous pythiosis after presenting with a nonhealing metatarsal wound, an inguinal mass, and regional lymphadenopathy. Both cytology of the abnormal lymph nodes and histopathology of the inguinal mass showed granulomatous inflammation. ELISA serology was positive for Pythium insidiosum. The dog developed
Brodkin J, Frederick SW, Rick M, Chapman PS.   +3 more
europepmc   +2 more sources

Hyperphosphatemia is a complication of reduced kidney functions and limit for renoprotection

Počki, 2020
Hyperphosphatemia in patients with chronic kidney disease (CKD) is an important complication of impaired renal function and is associated with negative clinical consequences such as cardiovascular calcification, bone disease and secondary ...
S.V. Kushnirenko
doaj   +1 more source

Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies [PDF]

, 2018
Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal recessive disorder of ectopic calcification due to deficiency of or resistance to intact fibroblast growth factor 23 (iFGF23). Inactivating
Burbelo, Christopher J. Romero, Daniela Egli-Spichtig, Emily Farrow, Farzana Perwad, Ichikawa, Lori C. Guthrie, Mary Scott Roberts, Michael J. Econs, Michael T. Collins, Peter D. Burbelo, Rachel I. Gafni, Shimada, Shoji Ichikawa, Uchida   +14 more
core   +1 more source